Tyrosine kinase inhibitor imatinib (STI571) as an anticancer agent for solid tumours

被引:80
作者
Joensuu, H
Dimitrijevic, S
机构
[1] Univ Helsinki, Cent Hosp, Dept Radiotherapy & Oncol, Helsinki, Finland
[2] Novartis Oncol, Basel, Switzerland
关键词
chronic myeloid leukaemia; c-kit; gastrointestinal stromal tumour; imatinib; platelet-derived growth factor receptor; positron emission tomography; sarcoma; signal transduction; STI571;
D O I
10.3109/07853890109002093
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Imatinib mesylate, also known as ST1571 or CGP57148, is a competitive inhibitor of a few tyrosine kinases, including BCR-ABL, ABL, KIT, and the plate let-derived growth factor receptors (PDGF-R). It binds to the ATP-binding site of the target kinase and prevents the transfer of phosphate from ATP to the tyrosine residues of various substrates. At oral doses of 300 mg or greater, the vast majority of patients with chronic myeloid leukaemia achieve a haematological response and this is usually associated with limited toxicity. Imatinib also has substantial activity in Philadelphia chromosome-positive acute lymphoblastic leukaemia expressing the BCR-ABL fusion protein. Gastrointestinal stromal tumours (GISTs) have also been evaluated for clinical activity of imatinib. About 90% of malignant GISTs harbour a mutation in c-kit leading to KIT receptor autophosphorylation and ligand-independent activation. According to initial clinical studies, more than 50% of GISTs respond to therapy within a few months, and only about 10-15% progress. The potential for cure and the optimal length of treatment are currently not known. Several other human cancers may over-express KIT or PDGF-R, and clinical trials to evaluate the role of imatinib in the treatment of such cancers are currently ongoing. Imatinib is an example of a specifically designed, highly targeted cancer therapy, which poses novel requirements for both pathology laboratories and clinicians in terms of identifying the major molecular mechanisms involved in tumour growth.
引用
收藏
页码:451 / 455
页数:5
相关论文
共 13 条
[1]  
[Anonymous], 2001, P AM SOC CLIN ONCOL
[2]   ZD1839 ('Iressa')1,2 as an anticancer agent [J].
Baselga, J ;
Averbuch, SD .
DRUGS, 2000, 60 (Suppl 1) :33-40
[3]  
Blanke CD, 2001, P AM SOC CLIN ONCOL, p1a
[4]   Stem cell factor and hematopoiesis [J].
Broudy, VC .
BLOOD, 1997, 90 (04) :1345-1364
[5]   CGP 57148, a tyrosine kinase inhibitor, inhibits the growth of cells expressing BCR-ABL, TEL-ABL, and TEL-PDGFR fusion proteins [J].
Carroll, M ;
OhnoJones, S ;
Tamura, S ;
Buchdunger, E ;
Zimmermann, J ;
Lydon, NB ;
Gilliland, DG ;
Druker, BJ .
BLOOD, 1997, 90 (12) :4947-4952
[6]   Two hundred gastrointestinal stromal tumors - Recurrence patterns and prognostic factors for survival [J].
DeMatteo, RP ;
Lewis, JJ ;
Leung, D ;
Mudan, SS ;
Woodruff, JM ;
Brennan, MF .
ANNALS OF SURGERY, 2000, 231 (01) :51-58
[7]   Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the philadelphia chromosome. [J].
Druker, BJ ;
Sawyers, CL ;
Kantarjian, H ;
Resta, DJ ;
Reese, SF ;
Ford, JM ;
Capdeville, R ;
Talpaz, M .
NEW ENGLAND JOURNAL OF MEDICINE, 2001, 344 (14) :1038-1042
[8]   Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. [J].
Druker, BJ ;
Talpaz, M ;
Resta, DJ ;
Peng, B ;
Buchdunger, E ;
Ford, JM ;
Lydon, NB ;
Kantarjian, H ;
Capdeville, R ;
Ohno-Jones, S ;
Sawyers, CL .
NEW ENGLAND JOURNAL OF MEDICINE, 2001, 344 (14) :1031-1037
[9]   Gastrointestinal stromal tumors: Their origin and cause [J].
Hirota S. .
International Journal of Clinical Oncology, 2001, 6 (1) :1-5
[10]   Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. [J].
Joensuu, H ;
Roberts, PJ ;
Sarlomo-Rikala, M ;
Andersson, LC ;
Tervahartiala, P ;
Tuveson, D ;
Silberman, SL ;
Capdeville, R ;
Dimitrijevic, S ;
Druker, B ;
Demetri, GD .
NEW ENGLAND JOURNAL OF MEDICINE, 2001, 344 (14) :1052-1056